Cargando…

Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer

The pan-HER tyrosine kinase inhibitor (TKI) neratinib is therapeutically active against metastatic breast cancers harboring activating HER2 mutations, but responses are variable and often not durable. Here we demonstrate that recurrent HER2 mutations have differential effects on endocrine therapy re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalra, Rashi, Chen, Ching Hui, Wang, Junkai, Salam, Ahmad Bin, Dobrolecki, Lacey E., Lewis, Alaina, Sallas, Christina, Yates, Clayton C., Gutierrez, Carolina, Karanam, Balasubramanyam, Anurag, Meenakshi, Lim, Bora, Ellis, Matthew J., Kavuri, Shyam M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Translational Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379360/ https://www.ncbi.nlm.nih.gov/pubmed/35736563 http://dx.doi.org/10.1158/0008-5472.CAN-21-3106

Ejemplares similares

The uncharted role of HER2 mutant alleles in breast cancer
por: Kalra, Rashi, et al.
Publicado: (2023)

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
por: Punturi, Nindo B., et al.
Publicado: (2021)

Effects of dacomitinib on the pharmacokinetics of poziotinib in vivo and in vitro
por: Ji, Weiping, et al.
Publicado: (2021)

Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
por: Kim, Tae Min, et al.
Publicado: (2018)

Diffuse scaly erythematous plaques in patient taking poziotinib
por: Oldenburg, Reid, et al.
Publicado: (2021)

Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib
por: Tchekmedyian, Nishan, et al.
Publicado: (2020)

Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer
por: Gou, Xuxu, et al.
Publicado: (2021)

Multiorgan Damage in Patients With COVID-19: Is the TGF-β/BMP Pathway the Missing Link?
por: Carlson, F. Roy, et al.
Publicado: (2020)

Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer
por: Gou, Xuxu, et al.
Publicado: (2023)

Inhibition of the Warburg effect with a natural compound reveals a novel measurement for determining the metastatic potential of breast cancers
por: Arora, Ritu, et al.
Publicado: (2015)

Poziotinib in non-small-cell lung cancer patients with HER2 exon 20 mutations: A pooled analysis of randomized clinical trials
por: Wang, Bi-Cheng, et al.
Publicado: (2022)

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer
por: Eli, Lisa D., et al.
Publicado: (2022)

Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer
por: McCorkle, J. Robert, et al.
Publicado: (2021)

Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC‐MS/MS
por: Wang, Shuanghu, et al.
Publicado: (2023)

Combined Poziotinib with Manidipine Treatment Suppresses Ovarian Cancer Stem-Cell Proliferation and Stemness
por: Lee, Heejin, et al.
Publicado: (2020)

Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial
por: Le, Xiuning, et al.
Publicado: (2022)

Neuroligin 4X overexpression in human breast cancer is associated with poor relapse-free survival
por: Henderson, Henry J., et al.
Publicado: (2017)

Molecular and pathological subtypes related to prostate cancer disparities and disease outcomes in African American and European American patients
por: Mori, Joakin O., et al.
Publicado: (2022)

HER3 Is an Actionable Target in Advanced Prostate Cancer
por: Gil, Veronica, et al.
Publicado: (2021)

Assessments of CYP‑inhibition‑based drug–drug interaction between vonoprazan and poziotinib in vitro and in vivo
por: Zhou, Shan, et al.
Publicado: (2023)

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
por: Khelwatty, Said A, et al.
Publicado: (2015)

Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method
por: Wang, Jinhui, et al.
Publicado: (2021)

A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
por: Lee, Ji Hyun, et al.
Publicado: (2021)

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
por: Evans, A H, et al.
Publicado: (2010)

Phage Ligands for Identification of Mesenchymal-Like Breast Cancer Cells and Cancer-Associated Fibroblasts
por: Jones, Kelvin M., et al.
Publicado: (2018)

Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells
por: Bruynzeel, A M E, et al.
Publicado: (2007)

HER2 expression as a potential marker for response to therapy targeted to the EGFR
por: Emlet, D R, et al.
Publicado: (2006)

Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma
por: De Silva, Nadeera, et al.
Publicado: (2015)

HER2 expression patterns in paired primary and metastatic endometrial cancer lesions
por: Halle, Mari Kyllesø, et al.
Publicado: (2018)

EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
por: Kumai, T, et al.
Publicado: (2013)

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
por: Tural, D, et al.
Publicado: (2014)

AR negative triple negative or “quadruple negative” breast cancers in African American women have an enriched basal and immune signature
por: Davis, Melissa, et al.
Publicado: (2018)

Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas
por: Berta, G N, et al.
Publicado: (2005)

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma
por: Kawaguchi, Y, et al.
Publicado: (2007)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
por: Peiró, G, et al.
Publicado: (2014)

Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies
por: Laux, I, et al.
Publicado: (2006)

Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice
por: Bruynzeel, A M E, et al.
Publicado: (2007)

Human responses against HER-2-positive cancer cells in human immune system-engrafted mice
por: De Giovanni, C, et al.
Publicado: (2012)

Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
por: Duro-Sánchez, Santiago, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ssneusc4dra5e52bhb071u106c